German biotech company Morphosys' tafasitamab, the group's most advanced drug which is currently being tested, has sales potential of significantly more than $1 billion a year, its finance chief said in remarks to a magazine.
from Reuters: Health News https://ift.tt/2R1ZcNj
via
IFTTT
0 comments:
Post a Comment